share_log

GlaxoSmithKline | 6-K: Gsk Announces Positive Results from Dreamm-8 Phase Iii Trial for Blenrep Versus Standard of Care Combination in Relapsed/Refractory Multiple Myeloma

GlaxoSmithKline | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

葛蘭素史克 | 6-K:外國發行人報告
SEC announcement ·  03/07 06:14
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息